original articleslung cancerOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
lung cancer
Under a Creative Commons license
open access
Keywords
bevacizumab
chemotherapy
NSCLC
overall survival
vascular endothelial growth factor
Cited by (0)
Copyright © 2010 European Society for Medical Oncology. Published by Elsevier Ltd.